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Abstract Portal vein embolization (PVE) has been
developed to increase the size of the future remnant liver
(FRL) left in place after major hepatectomy, thus reducing
the risk of postoperative liver insufficiency. PVE consist in
embolizing preoperatively portal branches of the segments
that will be resected. Indication is based on preoperative
measurements of the FRL by computed tomography and its
ratio with either the theoretical liver volume or by direct
measurement of the functional liver volume. After PVE,
the volume and function of the FRL increases in 3 to
6 weeks, permitting extensive resections in patients
otherwise contraindicated for liver resection. The PVE
technique is variable from one center to another; however
n-butyl-cyano-acrylate provides an interesting compromise
between hypertrophy rate and procedure risk.
Keywords Embolization  Embolotherapy 
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Introduction
Surgical resection of hepatic tumors is often the only
curative option in primary and secondary liver tumors that
may give patients a chance of long-term survival. How-
ever, the disease of many patients is considered unresec-
table because of an insufficient future remnant liver (FRL)
volume to be left in place after extended surgical resection.
The risk of liver failure after resection, as well as overall
postoperative morbidity are directly linked to the volume
of liver left in place by the surgeon [1]. In order to render
more cases amenable to curative resection, portal vein
embolization (PVE) is now an accepted technique to pre-
operatively increase the volume of the FRL.
PVE appeared in the late 1980s in Japan. In 1986, two
publications opened the gate for the development of this
technique. The first consisted of observations of hepatic
lobar atrophy due to lobar portal invasion by cholangio-
carcinoma [2]; the other consisted of a Japanese group’s
observations of atrophy of hepatic lobes in which they
embolized portal branches in order to limit intraportal
extension of hepatocellular carcinoma [3]. Simultaneously,
they both noticed than segments with patent portal bran-
ches increased in size over time. These clinical observa-
tions confirmed the experimental results obtained by Rous
and Larimore in the 1920s in a rabbit model of portal vein
ligation [4]. The technique of PVE gained rapidly popu-
larity in Japan in surgical groups treating hepatocellular
carcinoma and Klatskin tumors [2, 3, 5, 6]. The first group
that used PVE outside Japan was the Institut Gustave
Roussy group in Villejuif, France, with Thierry de Baere as
the interventional radiologist and Dominique Elias as the
liver surgeon [7]. The first report in North America was
that of David Madoff and Nicolas Vauthey from the MD
Anderson Cancer Center in Houston, Texas, in 2000 [8].
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Most liver surgeons have now endorsed this technique and
use it in daily practice.
How Does PVE Work?
PVE is used in patient candidates who require extensive
liver resection but have insufficient volume of FRL.
Basically, PVE consist in occluding portal branches of
segments that will be resected; the portal flow is then
abruptly entirely redistributed toward the FRL’s portal
branches [9]. The mechanism of liver regeneration after
PVE is a complex phenomenon that is not fully understood.
From a histologic point of view, PVE induces atrophy of
the embolized lobe as a result of both hepatocyte apoptosis
and sinusoid dilatation, while in the nonembolized lobe,
cells enter in an intense mitotic activity a few days after
PVE, thus accounting for increased FRL volume after
2–4 weeks [10].
The biologic and cellular mechanisms of liver regener-
ation have been studied mainly in rodent models and in
humans after extensive hepatectomy. From these publica-
tions, we know that hepatocytes that are usually quiescent
in the G0 phase (only 1 out of 2000–3000 hepatocytes
replicate in normal conditions) enter phase G1 one day
after hepatectomy. Kupffer cells, endothelial cells, and bile
duct cells replicate in a delayed fashion, suggesting that
hepatocyte replication triggers proliferation of other cells
[11]. After this initial phase of replication, hepatocytes
increase progressively in size, allowing for gross liver
growth [12]. Many molecular pathways are involved in
liver regeneration after hepatectomy, such as tumor
necrosis factor alpha, interleukin (IL) 6 produced by
Kupffer cells, hepatocyte growth factor produced by stel-
late cells, vascular endothelial growth factor, and platelet-
derived growth factor [13]. Platelets and serotonin have
also demonstrated their crucial role in liver regeneration
[14]. All these factors interact and overlap in their activities
and roles. Regeneration after PVE is somewhat different in
term of intensity, with lower production of IL-6, IL-1, and
tumor necrosis factor alpha after embolization. Mecha-
nisms of regeneration after PVE are also delayed compared
to regeneration after hepatectomy [15].
A deeper understanding of the mechanism involved in
liver regeneration is crucial to improve the results of PVE.
The role of heat shock protein 70 (a protein involved in cell
reparation mechanisms) has also been evaluated as induc-
tor of liver regeneration in human [16]. Miyake et al. have
shown an increase by two- or fourfold in the nonembolized
liver compared to embolized liver after PVE. Interestingly,
in their series, only one patient did not show increase of
heat shock protein 70 after PVE and subsequently died of
liver failure after hepatectomy. Some groups have even
explored the potential of heat shock protein 70 inducer
geranyl–geranyl–acetone to stimulate liver regeneration.
Administration of geranyl–geranyl–acetone increases tol-
erance to major hepatectomy but has never been tested in
combination to PVE [17].
Despite many interesting animal and experimental stud-
ies, the trigger of liver regeneration after PVE remains
unknown. The players are similar to those after hepatec-
tomy, but the initial phenomenon remains mysterious. Is it a
vascular stress in the FRL induced by abrupt portal redis-
tribution, or is it in the embolized liver that the process is
initiated by periportal inflammation? They remain open
questions. It is noteworthy that different studies identified
periportal inflammation in the embolized lobe from patho-
logic studies as an important predictor of liver regeneration,
both in human and experimental animal studies [18, 19].
How Are Patients Selected for PVE?
Selection of patients for PVE is decided during multidis-
ciplinary meetings and by tumor boards. The decision
directly depends on the planning of the surgery, the amount
of liver to be resected, and the functional status of the liver.
This risk is related to the volume of liver left in place after
surgery, to the function of the parenchyma (cirrhotic,
cholestatic, fibrotic, steatotic) [12], and to the complexity
of surgery that will prolong liver ischemia periods by
vessel clamping and will increase intraoperative blood loss,
and consequently will further increase risk of postoperative
liver failure. Therefore, selection for PVE is based on three
factors: liver volumetry as assessed by computed tomog-
raphy (CT), liver function test, and resection complexity.
Such ambitious surgical multistep projects are usually
proposed to motivated patients in good general condition.
The first factor is easily established by means of CT after
injection of contrast media. Attention should be paid to
having a sufficient enhancement of both portal branches and
hepatic veins to precisely delimit liver segments. Volumes
are then delineated by manually tracking the limits of seg-
ments and tumors and automatically calculating volumes
from axial slices. Recently, automatic recognition of liver
segments allowing for ‘‘automatic volumetry’’ have become
available from some companies [20].
Different methods have been used to determine the ratio
between the FRL and the total functional liver volume (FLR
ratio). Differences are related to the definition of total FLR.
Some authors use direct measurement of the total liver volume
minus tumor volume by CT [21–23]. Others use a standard-
ized evaluation of the normal liver volume in white subjects on
the basis of a formula using the formula body surface area
(total liver volume (cm3) = - 794.41 ? 1267.28 9 body
surface area (m2)) [24]. The last method is to express this ratio
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as a percentage of body weight [25, 26]. Shah et al. [25],
comparing these three ways to estimate the FLR ratio, found
that the best method to estimate the risk of postoperative liver
failure was the formula estimating liver volume from body
surface area described by Vauthey et al. [24]. The situation is
probably different in diseased or cirrhotic liver, but to our
knowledge, this has not been evaluated. In such conditions,
comparison of the FLR ratio threshold between one publica-
tion and another becomes complex and not very feasible
(Table 1). The consequence is that some groups, for patients
with normal liver, use a FLR threshold at 30% and others at
20% to decide PVE [26, 27].
Evaluation of liver function is more complex and
debated. Patients with cirrhosis have been extensively
studied in that regard, while patients treated by chemo-
therapy or with steatotic livers have been less studied. In
patients with cirrhosis, estimation of hepatectomy risk is a
conjunction of three elements: Child-Pugh score, mea-
surement of portal hypertension, and, in some groups,
indocyanine green (ICG) test. The latter evaluates both
global liver perfusion and biliary excretion by measuring
the extraction from the serum by the liver of ICG that is
excreted unchanged into the bile. An ICG retention rate of
[20% at 15 min is considered to be a contraindication for
resection [28]. Portal hypertension can be estimated by
direct measurement of hepatic vein pressure gradients, by
oesogastric endoscopy, or by imaging identification of
large porto–caval collaterals [29, 30]. Selection criteria for
other patients at high surgical risk are less established. For
instance, there is no universally accepted way to select in
patients treated by multiple courses of chemotherapy or
with metabolic syndrome and steatosis [31, 32].
Performing PVE in every patient before major resection
does not influence postoperative morbidity and mortality
[33]. The usual threshold accepted by most of the surgical
teams is as follows. In young patients with a normal liver
and without risk factors for liver surgery, a hepatectomy
removing 75–80% of the functional liver is acceptable. In
cirrhotic Child A patients with a portocaval gradient under
12 mm Hg, removing more than 60% of the liver volume is
considered to put the patient at risk of postoperative liver
failure. In patients with multiple courses of chemotherapy,
steatosis, and cholestatic liver, and a FRL to total liver ratio
of 20–40%, the decision is made on an individual, basis
taking all risk factors into consideration. A very small left
lobe (under 10%) should not be considered a contraindi-
cation; two recent studies have demonstrated in metastatic
patients and in cirrhotic patients that there is a correlation
between small initial size of the FLR and high degree of
hypertrophy [23, 34]. In other words, the smaller the left
lobe, the greater its hypertrophy after PVE.
Should We Evaluate Liver Volumes or Liver Volume
and Function by Nuclear Medicine?
Over the last few decades, scintigraphic techniques have
been used for noninvasive, direct evaluation of liver
function and have several benefits over the more estab-
lished, indirect method using CT volumetry [35].
99mTc-galactosyl human serum albumin (99mTc-GSA)
scintigraphy measures the binding of asialoglycoproteins
on its receptor, which is expressed only on the sinusoidal
surface juxtaposing the Disse space of the mammalian
hepatocytes [36]. The receptor is involved in the endocy-
tosis of the asialoglycoproteins subsequently degraded by
lysozymes. Over last few decades, several indices of liver
function have been developed in planar scintigraphy and
single-photon emission computed tomography (SPECT)
[35]. They show a good correlation with conventional liver
function tests, ICG clearance test, Child-Pugh classifica-
tion, and histology (hepatic index activity score). In 9–17%
of patients, there is a discrepancy between ICG clearance
testing and 99mTc-GSA scintigraphy; the latter better
reflects the histologic severity of liver function [37, 38] and
is not parasitized by hyperbilirubinemia.
Moreover, it is an independent predictor of postopera-
tive complications, in contrast to ICG. Concerning PVE,
99mTc-GSA SPECT scintigraphy demonstrated additional
value over CT volumetry for evaluating functional increase
after PVE [39–41], by demonstrating a higher increase in
function of the nonembolized liver by 99mTc-GSA SPECT/
CT than by CT-volumetry (?21.4% vs. ?13.9%,
P \ 0.001). In a similar study using 99mTc-GSA SPECT/
CT, criteria could be proposed on the basis of total amount
Table 1 Schematic description of the advantages and disadvantages
of ipsilateral and contralateral approaches for PVE
Pros
and
cons
Contralateral Ipsilateral
Pros Catheterism easier No risk for FRL
Final control
portography
easier
Easy puncture as a result of larger
portal branches
Use of NBCA Access to segment 4 branches
Cons Risk of
complications in
the FRL
Catheterism of right portal branches
more complex
(increased by
portal
hypertension)
Use of NBCA more tricky
Final control hard to achieve is
NBCA used
Risk of tumor seeding
Risk of liver infarction in case of
arterial complication during access
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of receptor in the remnant liver to select candidates for
PVE with good clinical outcome and thus expand the range
of hepatic resection [42]. Unfortunately, the 99mTc-GSA kit
is only commercially available in Japan and is not currently
available for use in Europe or the United States (Fig. 1).
The 99mTc-iminodiacetic acid (99mTc-IDA) derivative
scintigraphy has been used for more than three decades for
hepatobiliary scintigraphy. These lidocaine analogs are
transported to the liver mainly bound to albumin, where it is
cleaved in the Disse space. From there, 99mTc-IDA com-
pounds enter the basal membrane of the hepatocyte through
anion transporters before being excreted unmetabolized to
the biliary tract [43]—similar to ICG—by the ATP-depen-
dent export pump multidrug-associated protein 2. As these
agents follow a path similar to bilirubin or toxins, they have
been proposed as an index of liver function [44]. Of all
available IDA derivatives, 99mTc-mebrofenin is the agent of
choice, with high hepatic uptake, minimal urinary excretion,
and resistance to high levels of bilirubinemia. Hybrid
SPECT/CT acquisitions have been used to derive regional
liver function around the peak of the hepatic time–activity
curve, allowing calculation of remnant liver function on the
basis of contouring the liver outline via low-dose CT [45].
99mTc-mebrofenin scintigraphy has been validated in the
preoperative assessment of liver function [46, 47], with a
good correlation with ICG testing [48]. The combination of
dynamic hepatobiliary scintigraphy and SPECT to mor-
phologic volume measured by CT was able to accurately
predict actual postoperative liver function of the remnant
liver [45]. This technique is currently applied to measure
the regional increase in liver function after PVE. 99mTc-
mebrofenin scintigraphy could be used to select patients for
PVE thanks to its demonstrated ability to predict increased
postoperative liver failure [49]. A step in this direction was
taken using hypothetical values for safe resection in func-
tion and volume increase after PVE. De Graaf et al. [50]
showed that the increase in function as measured by 99mTc-
mebrofenin was larger than the increase in volume. This
suggests that the waiting time until resection may be
shorter than the 3–4 weeks indicated by volume expansion.
Thus, some authors advocate that function-based criteria,
in addition to volume-based criteria, should be used,
especially when liver resection needs to be performed with
minimal accepted remnant volume [51].
How Is PVE Performed?
The technique of PVE is extremely variable from one
center to another, depending on operator preference
(Table 1). The access route can be ipsilateral or contra-
lateral. Some authors use the ipsilateral approach, punc-
turing a right portal branch and embolizing in a retrograde
fashion all right portal branches. This access allows for an
easy catheterization of segment 4 branches when they must
be embolized. The drawback of this technique is mainly the
difficulty of access to the right portal branches in a retro-
grade fashion, and also sometimes the difficulty of finding
a route through healthy liver to the right portal branches
[6, 52]. The contralateral approach aims to puncture a left
peripheral portal branch (Fig. 1). Catheterization of the
right portal branches is theoretically easier, if anatomy is
standard. Such contralateral access renders final control
portography easier because the catheter does not have to
pass through embolic material to be placed in the portal
vein for final contrast injection [7, 23, 53]. Choosing the
access also depends on the embolic material used. Glue can
hardly be manipulated from the ipsilateral side, while large
embolic materials, like plugs, need large-diameter access,
which is less risky when obtained on the ipsilateral side
[54]. The final choice between the ipsilateral and contra-
lateral routes should be made by comparing their respective
complication rates. They seem similar and are mainly
related to puncture of unexpected structures, such as biliary
branches or hepatic arteries. The largest series of contra-
lateral PVE reviewed 188 cases at different centers using
contralateral access and n-butyl-cyanoacrylate as an
embolic material [55]. Only six of the 12 reported
Fig. 1 A 67-year-old man bearing four liver metastases in the right
lobe. The decision was made to perform PVE before right hemihep-
atectomy. A Segment 3 branch and portography in the right anterior
oblique view were obtained. B The right portal branches were
embolized with a mixture of NBCA and ethiodized oil. C Subtracted
portography after PVE showing complete redistribution toward the
left lobe. Parenchymatous enhancement was only evident on the right
side
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complications could be related to the access route, but none
precluded liver resection. It is also interesting to note that
these complications mainly occurred in patients with portal
hypertension. Another series reported similar rate of
complications using the ipsilateral route [56]. Finally,
arterial or biliary complications do not have the same
consequences if the portal vein is occluded or patent.
Embolization of a traumatized hepatic arterial branch may
lead to infarction on the ipsilateral side of PVE and have no
impact on the contralateral side. Our policy for right PVE
using n-butyl-cyano-acrylate (NBCA) is to use the con-
tralateral side. We use the ipsilateral side when segment 4
branches must be embolized and when the left lobe is quite
small and barely accessible. Other access routes have been
described through surgical dissection and catheterization of
the ileocolic vein. This access has the benefit of not
puncturing the liver, but it makes the procedure more
complex and catheter manipulation trickier [57].
Our recommendation and habit is to use the contralateral
access route and to embolize with NBCA mixed with
lipiodol. The risk of local complication is low and can be
managed without difficulty because the portal flow is
opened on this side (Fig. 1).
Which Embolic Material Should Be Used?
Various embolic materials have been used for PVE, including
Gelfoam [7], NBCA [23], different types and size of beads
[58, 59], alcohol [60], and nitinol plugs [54] (Table 2). All of
these embolic materials are able to occlude the right portal
branches and redistribute flow toward the FRL. There is no
official recommendation for a specific embolic material [61].
There is no single-center comparative study evaluating which
embolic material provide better hypertrophy, and comparison
between series are not helpful because these series have
neither standardized inclusion criteria nor standardized delay
after PVE for CT evaluation of hypertrophy (2–6 weeks). In
addition, the rate of hypertrophy after PVE depends on the
preembolization FRL volume more than any other factor, as
described previously [34].
However, the choice of the embolic material can be influ-
enced by the results of experimental studies. Recently, De
Baere et al. have compared in a pig model three commercially
available embolic materials: NBCA mixed with iodized oil,
and two different sizes of spherical particles. NBCA seemed to
be more efficient in including liver regeneration than spherical
particles. A correlation of periportal fibrosis in the embolized
lobe and liver regeneration was also found [19]. This result is
in concordance with previous observations in human. If par-
ticles are used, more significant hypertrophy is obtained with
small-size spherical particles compared to larger-size or non-
spherical particles [62].
Should PVE or Surgical Ligation of the Right Portal
Branches Be Performed?
Surgical ligation of the right portal branches is an invasive
surgical procedure requiring dissection of the liver hilum
during a laparotomy. Controversy exists about the respec-
tive indications of PVE and ligation. Portal vein ligation
seems efficient to induce left lobe hypertrophy [63, 64], but
because of its invasiveness, it is mainly used in the
so-called two-stage hepatectomy [65]. Patients with bilobar
metastases are operated on for resection of left lobe
metastases, and right portal vein ligation is achieved in the
same procedure. Four to 5 weeks thereafter, the left liver
has increased in size, and right hepatectomy can be per-
formed. However, portal vein ligation does not occlude
distal portal branches; the development of multiple intra-
hepatic porto–portal collaterals—namely from segment 4
to segments 5 and 8—is possible [66]. Even if portal vein
ligation allows for a two-stage hepatectomy, another option
in bilobar disease with small-size tumor in the left is
radiofrequency ablation of the left liver metastases and
PVE in the same procedure [67], followed 4 weeks later by
right hemihepatectomy.
Animal studies have conflicting results comparing
regeneration rate after portal vein ligation or embolization.
Studies in rats demonstrated superiority of ligation [68],
while more recent studies have shown the opposite in lar-
ger animals (pigs and rabbits) [69, 70]. The explanation
might be that the liver in rodents are almost foliated with
separated liver segments, while in pigs and in rabbits
intrahepatic porto–portal collaterals developed, thus prob-
ably limiting the occlusive effect of ligation. Furthermore,
hilar dissection in rats is probably associated by arterial
lesions in the ligated segments, increasing the effect of
portal ligation.
Should Segment 4 Branches Be Embolized?
In a prospective study analyzing liver volumes in a normal
population [71], volumes of segments 2 and 3 have shown
to account for less than 20% of the total liver volume in
nearly 80% of the population. In other words, PVE should
be performed in 80% of the cases when an extended right
hepatectomy has to be performed. The question is in these
cases is, should we or should we not embolize segment 4
branches? The results described in the literature are con-
troversial. Two elements should be kept in mind when
evaluating patients for segment 4 embolization. First, the
procedure is much more complex and can hardly per-
formed from the contralateral approach. This implies that
NBCA will probably not be used, and that a very careful
embolization will be performed on these branches with
A. Denys et al.: Portal Vein Embolization 1003
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particles and coils. This also means that the surgeon will
have to resect segment 4 in toto, which is rarely the case in
clinical practice. Because segment 4 has multiple portal
branches, it can also be resected incompletely, leaving
more parenchyma postoperatively.
Madoff et al. initially reported that embolization of
segment 4 branches nearly double the rate of hypertrophy of
the left lobe [62]. These results have not been found in other
experienced centers, which have even observed the contrary
[34, 72]. These groups observed maintained hypertrophy of
segment 4 after embolization of segment 4 branches. They
suggested that segment 4 portal-branch embolization is
rarely complete, and that persistent patent segment 4 portal
branches account for maintained regeneration.
What Should Be Done If Hypertrophy Is Insufficient
after PVE?
This situation is more frequent when considering patients
with chronic liver disease. Indeed, in a retrospective anal-
ysis of 42 consecutive cases, we observed nearly 10% of
patients without significant hypertrophy after PVE [23].
These patients were not operated on because insufficient
hypertrophy after PVE is usually considered a risk factor for
liver insufficiency after PVE. For some authors, a degree of
hypertrophy estimated as a percentage of increase of the
FRL below 10% in patients having chronic liver disease is
an indication of high risk of liver insufficiency [33]; the
same was observed with a degree of hypertrophy of 5% for
patients with normal liver [73]. Associated risk factors for
liver insufficiency in patients after hepatectomy prepared by
PVE are associated jaundice and extensive dissection of the
hepaticoduodenal ligament [74].
In cases of patients with chronic liver disease, it may be
necessary to wait longer (6–8 weeks after PVE) to obtain
sufficient hypertrophy. A recent study has demonstrated
that hypertrophy and regeneration may continue over a
1-year period after PVE [75].
Can We Predict Liver Regeneration after PVE?
There is no way to predict hypertrophy after PVE. Many
factors have been identified and influence regeneration.
However, the most significant factor is the size of the FRL
before PVE [23, 34], in cases of both healthy liver and
chronic liver disease. This means that surgeons and inter-
ventionalist should not preclude PVE in case of very small
left liver volumes, but on the contrary expect marked
hypertrophy in these cases. Indeed, PVE was able to pro-
vide enough hypertrophy to convert the patient to surgery
with a FRL as low as 6.9%, which clearly open the gate for
resection of all the liver except one segment—a notion that
to our knowledge has never been explored. Other factors
identified as decreasing the rate of regeneration must be
kept in mind, and in these cases, PVE can be considered as
a test for the capacity of the liver to regenerate. Factors
known to negatively influence regeneration include diabe-
tes, liver fibrosis F4, cholestasis, and portal hypertension.
Other factors are known to have no influence on liver
regeneration, including sex age, origin of the tumor, che-
motherapy with anti–vascular endothelial growth factor
such as bevacizumab, and ICG clearance [76]. Chemo-
therapy with oxaliplatin may induce severe sinusoidal
obstruction and subsequent portal hypertension, making
PVE more difficult and potentially more at risk of com-
plications [77] (Fig. 2).
Fig. 2 A 45-year-old woman treated with six cycles of chemotherapy
with oxaliplatin, 5-fluorouracil, and folinic acid. Because of the
presence of stable disease, right hepatectomy was chosen. Because
FRL ratio is 28%, and taking into account the percutaneous
destruction of a small segment 3 lesion, a right PVE was performed.
A T1-weighted axial image identifying both right hepatic lobe
metastases and small nodular lesion in segment 3 (arrow). B After
PVE, portography confirmed occlusion of right portal branches, and
the hepatofugal paraumbilical vein was identified (white arrows). C A
control CT was performed 1 month after PVE, revealing partial
thrombosis of the portal vein trunk (arrow), while segments 2, 3, and
4 increased in size. D During hepatectomy, right portal vein ligation
was made more complex by portal vein thrombosis and stenosis of the
portal vein associated with portal hypertension after hepatectomy
induced complete portal vein thrombosis at postoperative CT (arrow)
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Is Surgery More Complex after PVE?
Complications after PVE should not be underestimated and
may impair future surgery. Hematoma, hemobilia, and
sepsis, as well as embolization material going to the non-
embolized lobe, resulting in partial or complete portal vein
thrombosis, are rare but may be serious problems for sur-
gery [34]. For surgical strategy in cases of hilar cholangi-
ocarcinoma, it is important to preoperatively precisely
determine the liver side to be embolized and resected. It is
obvious that once the PVE is performed, an intraoperative
change in the resection strategy is no longer possible, thus
making a preoperative precise diagnosis mandatory before
PVE [78].
Even without PVE-induced complications, postopera-
tive complications of major liver surgery after PVE are
increased, with a clear trend for higher intraoperative
bleeding from the dilated intrahepatic venous collateral
[34, 79–81].
In fact, operation duration after PVE is significantly
longer, and there is increased blood loss. The postoperative
complication rate after PVE is about 40%, with mortality at
30, 60, and 90 days of 2%, 4.7%, and 6%, respectively
[81]. This increased morbidity and blood loss are due in
part to more complex resection, but also to the above-
mentioned dilated collateral veins after PVE. The impor-
tant point is that blood loss has been correlated with
impaired postoperative liver regeneration in an experi-
mental model [82]. This is correlated with clinical studies
that reveal blood transfusion to be an independent predic-
tive factor for postoperative liver insufficiency [81, 83].
Major postoperative changes in portal blood flow after
PVE followed by extensive liver resection are observed.
The volume of portal blood flow may increase up to
threefold and may lead to a relative venous outflow block
and liver congestions, thus forming a small-for-size liver
[78].
Conclusion
PVE is a well-established technique. It is now used
worldwide to enhance patient safety after major hepatec-
tomy. This technique is probably still in its infancy;
regeneration enhancers, safer embolic material, association
to hepatic vein embolization are many new ways that will
permit more aggressive surgical options. Removing all the
liver except for one segment is still a utopian ideal—but
probably not for long.
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